Generic Name: encorafenib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Array BioPharma/Pfizer

Approval Status: Approved

Generic Version Available: No

Experimental Code: LGX818

Drug Indication

Braftovi is a kinase inhibitor approved as a component of targeted therapy for metastatic melanoma and metastatic colorectal cancer.

General Info

Braftovi is a kinase inhibitor that targets cancers with BRAF V600 mutations. The BRAF gene encodes an enzyme that plays a role in tumor development.

The Phase III COLUMBUS trial showed that Braftovi in combination with Mektovi (binimetinib) delayed disease progression in people with inoperable or metastatic melanoma with a BRAF V600E or V600K mutation. The Phase III BEACON study showed that Braftovi plus Erbitux (cetuximab) improved overall survival and progression-free survival in patients with metastatic colorectal cancer with a BRAF V600E mutation. Braftovi was first approved in 2018.


Dosing Info:

Braftovi is taken as a capsule once daily with Mektovi (for melanoma) or Erbitux (for colorectal cancer). It can be taken with or without food.

Side Effects

Common side effects include fatigue, nausea, vomiting, diarrhea, abdominal pain, decreased appetite, joint pain and skin rash. Potential serious side effects may include new malignancies, heavy bleeding, eye inflammation and vision disturbances and heart rhythm abnormalities. Braftovi can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: April 10, 2020